Abstract P1-09-06: Evaluation of proliferation biomarker serum thymidine kinase activity and prediction of early relapse in HR positive HER2 negative high risk early breast cancer: Analysis from the PENELOPE-B trial
Amy J. Williams(University of Florida), Sibylle Loibl(Goethe University Frankfurt), Frederik Marmé(Heidelberg University), Federico Rojo(Hospital Universitario Fundación Jiménez Díaz), Peter A. Fasching(Universitätsklinikum Erlangen), Erik Knudsen, Sung‐Bae Kim(Ulsan College), José Á. García-Sáenz(Hospital Clínico San Carlos), Martin Filipits(University of Vienna), Christian Schem(Krankenhaus Jerusalem), Carsten Denkert(Philipps University of Marburg), Agnieszka K. Witkiewicz(Roswell Park Comprehensive Cancer Center), Olga Valota, Karsten Weber(OTH Regensburg), Nicole Mc Carthy, Toralf Reimer(University of Rostock), Valentina Nekljudova, Nicholas C. Turner(Institute of Cancer Research), Harry D. Bear(Virginia Commonwealth University), Bärbel Felder, Lesley‐Ann Martin(Institute of Cancer Research), Zhe Zhang(Peking University), Laura van’t Veer(University of California, San Francisco), Masey M. Ross, Seock-Ah Im(Seoul National University Hospital), Angela DeMichele(University of Pennsylvania)
Cited by 1
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
|New England Journal of Medicine|2015|1.6k